You are here

Article Text

Article menu
Download PDFPDF
Letter
Impact on gonorrhoea case reports through concomitant/dual testing in a chlamydia screening population in Liverpool
  1. Sara Jayne Lavelle1,
  2. H Mallinson2,
  3. S J Henning3,
  4. A M C Webb4,
  5. S Hughes5,
  6. M Abbott6
  1. 1Liverpool, Sefton and Knowsley Chlamydia Screening Programme, Liverpool, UK
  2. 2Clinical Microbiology and HPA Collaborating Laboratory, University Hospital Aintree, Aintree, Liverpool, UK
  3. 3Cheshire and Merseyside Sexual Health Network, Tranmere, Cheshire, UK
  4. 4Abacus Clinics for Contraception and Reproductive Health Care, Liverpool, UK
  5. 5North West Public Health Observatory/HPA North West, Liverpool, UK
  6. 6Genito-Urinary Medicine Department, Southport and Ormskirk Hospitals NHS Trust, Southport, UK
  1. Correspondence to:
 Sara Jayne Lavelle
 Liverpool, Sefton and Knowsley Chlamydia Screening Programme; sara.lavelle{at}liverpoolpct.nhs.uk

https://doi.org/10.1136/sti.2007.027870

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A recent Commentary in this journal1 encourages wider implementation of nucleic-acid amplification tests (NAATs) to detect gonorrhoea (GC). We have used GC NAATs (APTIMA Combo2; Gen-Probe Inc., San Diego, California, USA) since 2003, with high uptake, in a Liverpool chlamydia screening population and with referral of GC-positive patients to our local genitourinary medicine (GUM) clinic for management.2 We have now observed a doubling of female cases of GC and a reversal of the downward trend for male …

    View Full Text

    Footnotes

    • Competing interests: None declared